期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

中性内肽酶抑制药在心血管疾病治疗中的应用 被引量：1

Application of neutral endopeptidase inhibitor in treatment of cardiovascular diseases
下载PDF
导出
摘要 中性内肽酶抑制药通过抑制中性内肽酶 ,延迟缓激肽分解 ,抑制血管紧张肽Ⅱ和内皮素生成等机制发挥扩血管 ,改善血管内皮功能、促进排钠利尿等作用 ,在高血压、心力衰竭等疾病的治疗中发挥重要作用。 Neutral endopeptidase inhibitor performs its function of dilating vessel, improving endothelial function and promoting natriuresis th rough inhibiting neutral endopeptidase, delaying bradykinin decomposition and in hibiting angiotensin II and endothelin production. It plays important role in th e treatment of hypertension and heart failure.
作者 黄震华
机构地区 上海第二医科大学附属第九人民医院心血管病研究室
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第2期108-111,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 内肽酶类 蛋白酶抑制药 高血压 心力衰竭 充血性 endopeptidases protease inhibitor hypertension heart failure, congestive
分类号 R972 [医药卫生—药品] R54 [医药卫生—心血管疾病]
  • 相关文献

参考文献3

二级参考文献35

  • 1[1]Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia[J]. Drugs 1996; 51: 433-59.
  • 2[2]Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia[J]. Atherosclerosis 1996; 119: 203-13.
  • 3[3]Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase[J]. Am J Cardiol 1994; 73 Suppl D: 3D-11D.
  • 4[4]Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia[J]. JAMA 1996; 275: 128-33.
  • 5[5]Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease[J]. Drugs 1997; 53: 299-336.
  • 6[6]Bocan TMA, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation[J]. Atherosclerosis 1994; 111: 127-42.
  • 7[7]Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias[J]. Drugs 1997; 53: 828-47.
  • 8[8]Heinonen TM, Stein E, Weiss SR, et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a double-masked study[J]. Clin Ther 1996; 18: 853-63.
  • 9[9]Naoumova RP, Marais D, Firth JC, Neuwirth CKY, Taylor GW, Thompson GR. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting upregulation of cholesterol synthesis after apheresis and bile acid sequestrants[J]. Circulation 1996; 94(8 Suppl): 583.
  • 10[10]Heinonen T, Black D. Atorvastatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia[J]. Atherosclerosis 1995; 115 Suppl: S20.

共引文献46

同被引文献31

引证文献1

二级引证文献3

中国新药与临床杂志
2004年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部